Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pradefovir (Remofovir) is a reverse transcriptase inhibitor potentially for treatment of chronic HBV infection. Pradefovir is also a liver-targeted prodrug of adefovir. After metabolic activation, Pradefovir was converted to PMEA (9-(2-phosphonylmethoxyethyl)adenine) in human liver microsomes with a K(m) of 60 microM, a maximum rate of metabolism of 228 pmol/min/mg protein, and an intrinsic clearance of about 359 ml/min.
説明 | Pradefovir (Remofovir) is a reverse transcriptase inhibitor potentially for treatment of chronic HBV infection. Pradefovir is also a liver-targeted prodrug of adefovir. After metabolic activation, Pradefovir was converted to PMEA (9-(2-phosphonylmethoxyethyl)adenine) in human liver microsomes with a K(m) of 60 microM, a maximum rate of metabolism of 228 pmol/min/mg protein, and an intrinsic clearance of about 359 ml/min. |
別名 | ICN-2001-3, MB-6866, ICN-20013, MB-06866, Remofovir |
分子量 | 423.79 |
分子式 | C17H19ClN5O4P |
CAS No. | 625095-60-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Soluble
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pradefovir 625095-60-5 Microbiology/Virology HBV ICN 20013 MB 6866 ICN-2001-3 MB-6866 ICN20013 MB6866 MB 06866 ICN-20013 MB-06866 Remofovir MB06866 Inhibitor inhibitor inhibit